# A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

> **NCT05091541** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanjing IASO Biotechnology Co., Ltd.** · enrollment: 125 (estimated)

## Conditions studied

- B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection

## Key facts

- **NCT ID:** NCT05091541
- **Lead sponsor:** Nanjing IASO Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-10-20
- **Primary completion:** 2024-10-20
- **Final completion:** 2039-10-20
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05091541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05091541, "A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05091541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*